Trastuzumab is a first choice for treatment of HER2-positive breast cancer in our cohort, but camptothecin (CPT) is often chosen as a regular regimen for HER2-negative breast cancer cases (Table 1). This evidence concerns the gene ERBB2 and breast carcinoma.